Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions

NCT03289260 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.

NCT NCT03289260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03289260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions
Lead sponsor
Medical University Innsbruck
Phase
Phase 3
Overall status
Unknown status
Start date
November 15, 2021
Completion date
November 15, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anogenital human papillomavirus infection, condyloma anal